Skip to main content

Advertisement

Table 3 Percentage of difference of PET parameters in non-responder group

From: A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions

Type of lesions SUVmax SUVmean Isocontour (Bq/mL) Isocontour-mediastinal
activity (Bq/mL)
Malignant lesion −4.71 −4.89 −16.36 −12.98
Gastrointestinal cancer −5.88 −4.68 −11.64 −8.74
Hepatobiliary and pancreatic cancer −6.71 −4.64 −17.34 −8.48
Hepatocellular carcinoma −1.64 −5.30 −25.52 −26.99
Inflammatory lesion −10.21 −6.17 −32.22* −45.70*
  1. *P < 0.05 when compared parameters between the first day and second day